Importantly, we show that this phenotype of cancer cells that is triggered by NRAS is not due to enhanced growth capacities conferred by the oncogene, but rests on inflammatory chemokine signaling to cognate receptors on host lung endothelial and myeloid cells and can thus be targeted by chemokine receptor inhibition. This evidence concerns the gene NRAS and cancer.